Clinical Trials Logo

Clinical Trial Summary

To ensure adequate seal of currently available stent grafts, a proximal 20 mm of healthy aorta is recommended. Extending the proximal landing zone into the arch by intentional covering of the left subclavian artery (LSA) without revascularization expose to serious neurologic complications. Serious risks are also known to accompany subclavian revascularization. The Valiant Mona LSA Thoracic Stent Graft System (Medtronic,Santa Rosa, Calif) consists of a main stent graft and a branch stent graft designed to maintain LSA patency. The purpose of this study is to characterize the safety and effectiveness of this device for the treatment of Aneurysms and chronic Type B dissections of the arch.


Clinical Trial Description

Stent graft coverage of the left subclavian artery (LSA) may be required to achieve an adequate landing zone in up to 40% of descending thoracic aneurysms (DTAs). To ensure adequate seal of currently available off-the-shelf stent grafts, 20 mm of healthy aorta is recommended between the proximal neck of the aneurysm and the leading edge of the stent graft. Stent graft placement can be facilitated by extending the proximal landing zone into the arch and covering the LSA; however, there may be a higher risk of serious neurologic outcomes (cerebral and paraplegia), although this is still a matter of debate. Serious risks are also known to accompany subclavian revascularization, which may involve bypass or transposition. The Valiant Mona LSA Thoracic Stent Graft System (Medtronic,Santa Rosa, Calif) consists of a main stent graft and a branch stent graft designed to maintain LSA patency while diverting circulation through the encroaching aneurysm.

The purpose of the feasibility study is to characterize the safety of the Valiant Mona LSA Thoracic Stent Graft System, including an assessment of the safety and effectiveness of the device acutely and at the 1-month visit in the identified subject population (Aneurysms and chronic, Type B dissections). A follow up of this population will be annually during 5 years.

This pilot, non-randomized, single-arm prospective study will concern 20 patients. Inclusion criteria required patients with a thoracic aortic aneurysm (TAA) or dissection with an indication of a stent-Graft insertion. Primary end points will be aneurysm-related mortality, stroke, paraplegia, left arm/hand ischemia, and treatment success. Technical success will be assessed by imaging at 1 month, 6 months then annually during 5 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03738124
Study type Interventional
Source University Hospital, Toulouse
Contact
Status Withdrawn
Phase N/A
Start date January 2019
Completion date February 2026

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02777593 - Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2 N/A
Completed NCT02876263 - Noninvasive Neuromonitoring of Surgery of the Thoracic Aorta N/A
Terminated NCT02538822 - Risk of Rupture of Aneurysms of the Thoracic Ascending Aorta (ATA) From the Dynamic Imaging N/A
Completed NCT04930172 - TOtal tRansfemoral branCHed endovasCular tHoracoabdominal Aortic Repair Registry
Completed NCT03207568 - RE-GENERATION: The Safety and Performance of the Relay Pro and Relay NBS Pro Stent-graft Devices in the European Union (EU) N/A
Recruiting NCT03010514 - A Registry Study on Genetics and Biomarkers of Thoracic Aortic Aneurysm/Dissection N/A
Completed NCT02266342 - GORE® TAG® Thoracic Endoprosthesis French Mandatory Registry
Completed NCT00757003 - To Evaluate the Safety and Efficacy for GORE TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Disease Phase 3
Recruiting NCT03574311 - Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Cardiac Surgery Phase 4
Suspended NCT03410420 - Detection of Hypoxia in Human Thoracic Aorta Using Pimonidazole Hydrochloride Phase 1
Recruiting NCT05703893 - Investigation of the Neurovegetative Pattern in Patients With Thoracic Aortic Aneurysms (TAA)
Enrolling by invitation NCT05800743 - Evaluation of the GORE® Ascending Stent Graft N/A
Completed NCT02253082 - Vasculopathic Injury and Plasma as Endothelial Rescue - OCTAplas Trial (EudraCT no. 2014-000452-28) Phase 4
Recruiting NCT02323581 - Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts N/A
Active, not recruiting NCT03414866 - Thoraflex Hybrid Post-Market Study
Recruiting NCT01985906 - Safety and Efficacy of Multiple Overlapping Uncovered Stents for Pararenal Aortic Aneurysm Repair N/A
Active, not recruiting NCT02818972 - RelayPro Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers N/A
Completed NCT03479164 - Development of Ultra-Low Dose CT Based Screening for Aortic Aneurysms N/A
Completed NCT01775046 - Valiant Thoracic Stent Graft With the Captivia Delivery System in the Treatment of Descending Thoracic Aortic Diseases (VALIANT CAPTIVIA France)
Recruiting NCT04814238 - Minimally Invasive Aortic Root and Aorta surGery rEgistry